Imugene Ltd (ASX: IMU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Imugene Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Imugene Ltd (ASX: IMU)
Latest News
Share Gainers
Why Imugene, Neuren, Sigma, and Smartgroup shares are charging higher
Share Gainers
Why Core Lithium, Imugene, Lifestyle Communities, and Mineral Resources shares are charging higher
Share Market News
Guess which ASX 300 stock is jumping 11% on big news
Healthcare Shares
2 All Ords ASX healthcare shares making BIG moves on quarterly updates
Share Fallers
Why AGL, Imugene, Star, and Woolworths shares are dropping today
Share Gainers
Why Appen, Cettire, DroneShield, and Imugene shares are racing higher
Healthcare Shares
Why this ASX All Ords stock is soaring 30% on Monday
Share Gainers
Why Catalyst Metals, Imugene, Red 5, and Telstra shares are pushing higher today
Share Gainers
2 ASX shares roaring higher on big news
Healthcare Shares
3 ASX healthcare shares outperforming on quarterly updates
Healthcare Shares
Broker says this ASX biotech stock could almost double in value
Share Gainers
Why Imugene, Liontown, Pointsbet, and Regis Resources shares are storming higher
Frequently Asked Questions
-
Imugene does not pay dividends at this stage.
-
Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.
IMU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Imugene Ltd
Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.
The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.
The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu.
Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.
IMU Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
08 Nov 2024 | $0.05 | $0.00 | 0.00% | 19,675,024 | $0.05 | $0.05 | $0.05 |
07 Nov 2024 | $0.05 | $0.00 | 0.00% | 9,482,751 | $0.05 | $0.05 | $0.04 |
06 Nov 2024 | $0.05 | $0.00 | 0.00% | 19,428,279 | $0.05 | $0.05 | $0.04 |
05 Nov 2024 | $0.05 | $0.00 | 0.00% | 20,445,375 | $0.05 | $0.05 | $0.05 |
04 Nov 2024 | $0.04 | $0.00 | 0.00% | 7,968,778 | $0.05 | $0.05 | $0.04 |
01 Nov 2024 | $0.05 | $0.00 | 0.00% | 16,769,572 | $0.04 | $0.05 | $0.04 |
31 Oct 2024 | $0.04 | $0.00 | 0.00% | 47,858,314 | $0.05 | $0.05 | $0.04 |
30 Oct 2024 | $0.05 | $0.00 | 0.00% | 9,762,599 | $0.05 | $0.05 | $0.05 |
29 Oct 2024 | $0.05 | $0.00 | 0.00% | 29,436,994 | $0.05 | $0.05 | $0.05 |
28 Oct 2024 | $0.05 | $0.00 | 0.00% | 5,733,798 | $0.05 | $0.05 | $0.05 |
25 Oct 2024 | $0.05 | $0.00 | 0.00% | 13,324,228 | $0.05 | $0.05 | $0.05 |
24 Oct 2024 | $0.05 | $0.00 | 0.00% | 10,740,305 | $0.05 | $0.05 | $0.05 |
23 Oct 2024 | $0.05 | $0.00 | 0.00% | 14,787,054 | $0.05 | $0.05 | $0.05 |
22 Oct 2024 | $0.05 | $0.00 | 0.00% | 6,721,583 | $0.05 | $0.05 | $0.05 |
21 Oct 2024 | $0.05 | $0.00 | 0.00% | 11,340,232 | $0.05 | $0.05 | $0.05 |
18 Oct 2024 | $0.05 | $0.00 | 0.00% | 10,660,723 | $0.05 | $0.05 | $0.05 |
17 Oct 2024 | $0.05 | $0.00 | 0.00% | 8,542,351 | $0.05 | $0.05 | $0.05 |
16 Oct 2024 | $0.05 | $0.00 | 0.00% | 18,373,903 | $0.05 | $0.05 | $0.05 |
15 Oct 2024 | $0.05 | $0.00 | 0.00% | 21,177,715 | $0.05 | $0.05 | $0.05 |
14 Oct 2024 | $0.05 | $0.00 | 0.00% | 35,095,628 | $0.05 | $0.06 | $0.05 |
11 Oct 2024 | $0.05 | $0.00 | 0.00% | 3,692,150 | $0.05 | $0.05 | $0.05 |
10 Oct 2024 | $0.05 | $0.00 | 0.00% | 11,930,066 | $0.05 | $0.05 | $0.05 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
01 Jul 2024 | Leslie (Mi Ok) Chong | Transfer | 1,500,000 | $82,500 |
As advised by the company. Transfer from direct to indirect holding
|
01 Jul 2024 | Leslie (Mi Ok) Chong | Buy | 5,793,750 | $318,656 |
Conversion of securities.
|
01 Jul 2024 | Leslie (Mi Ok) Chong | Exercise | 5,793,750 | $318,656 |
Conversion of securities. 17,381,250 RIGHTS
|
01 Jul 2024 | Leslie (Mi Ok) Chong | Transfer | 1,500,000 | $82,500 |
As advised by the company. Transfer from direct to indirect holding
|
01 Jul 2024 | Paul Hopper | Exercise | 975,375 | $53,645 |
Conversion of securities. 2,926,125 PERFORMANCE RIGHTS AWARD
|
01 Jul 2024 | Paul Hopper | Issued | 975,375 | $53,645 |
Conversion of securities.
|
01 Jul 2024 | Lesley Russell | Issued | 250,000 | $13,750 |
Conversion of securities.
|
01 Jul 2024 | Lesley Russell | Exercise | 250,000 | $13,750 |
Conversion of securities. 750,000 - Restricted Stock Units
|
01 Jul 2024 | Jens Eckstein | Exercise | 250,000 | $13,750 |
Conversion of securities. 750,000 RSU
|
01 Jul 2024 | Jens Eckstein | Issued | 250,000 | $13,750 |
Conversion of securities.
|
01 Jul 2024 | Jakob Dupont | Issued | 250,000 | $13,750 |
Conversion of securities.
|
01 Jul 2024 | Jakob Dupont | Exercise | 250,000 | $13,750 |
Conversion of securities. 750,000 - Restricted Stock Units
|
01 Jul 2024 | Kim Drapkin | Exercise | 250,000 | $13,750 |
Conversion of securities. 750,000 - Restricted Stock Units
|
01 Jul 2024 | Kim Drapkin | Issued | 250,000 | $13,750 |
Conversion of securities. As per announcement on 08-07-2024
|
19 Apr 2024 | Paul Hopper | Sell | 5,242,277 | $381,113 |
On-market trade.
|
18 Apr 2024 | Paul Hopper | Sell | 4,500,000 | $363,600 |
On-market trade.
|
17 Apr 2024 | Paul Hopper | Sell | 4,380,952 | $365,285 |
On-market trade.
|
01 Feb 2024 | Paul Hopper | Issued | 110,790,024 | $1,717,245 |
Issue of securities. Subject to release from escrow, as per announcement on 01-02-2024
|
01 Feb 2024 | Paul Hopper | Issued | 1,381,422 | $21,412 |
Issue of securities. Subject to release from escrow, as per announecment on 01-02-2024
|
01 Feb 2024 | Paul Hopper | Transfer | 10,000,000 | $1,000,000 |
As advised by the company. Transfer of shares for nil
consideration. |
12 Jan 2024 | Leslie (Mi Ok) Chong | Issued | 23,175,000 | $2,781,000 |
Issue of securities. 23,175,000 - Performance Rights
|
12 Jan 2024 | Paul Hopper | Issued | 3,901,500 | $468,180 |
Issue of securities. 3,901,500 - Performance Rights
|
12 Jan 2024 | Lesley Russell | Issued | 1,000,000 | $120,000 |
Issue of securities. 1,000,000 - RSUs
|
12 Jan 2024 | Jakob Dupont | Issued | 1,000,000 | $120,000 |
Issue of securities. 1,000,000 - RSUs
|
12 Jan 2024 | Jens Eckstein | Issued | 1,000,000 | $120,000 |
Issue of securities. 1,000,000 - RSUs
|
12 Jan 2024 | Kim Drapkin | Issued | 1,000,000 | $120,000 |
Issue of securities. 1,000,000 - RSUs
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Ms Leslie (Mi Ok) Chong | Chief Executive OfficerManaging Director | Nov 2016 |
Ms Chong joined the Group from the leading oncology clinical development company, Genentech (a member of the Roche family), where she was a Senior Clinical Program Lead at the head office in San Francisco. She has over 25 years of experience in leading clinical and department development in oncology. In November 2016, Former directorships in last three years - Cure Brain Cancer Foundation (non-profit organisation), until 11 April 2023.
|
Mr Paul Alex Hopper | Executive ChairmanExecutive Director | Dec 2013 |
Mr Hopper has over 20 years of experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered therapeutic areas with emphasis on immunotherapy. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. Former directorships in last three years include Scopus BioPharma Inc (NASDAQ: SCPS), until 18 May 2022.
|
Dr Lesley Russell | Non-Executive Director | Apr 2019 |
Dr Russell is a haematologist/oncologist and has over 25 years of experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology and has had new drug approvals with FDA and European Medicines Agency. Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK. Other current directorships - Enanta Pharmaceuticals (NASDAQ: ENTA), since 22 November 2016. Dr Russell is member of Risk Committee.
|
Dr Jens Eckstein | Non-Executive Director | May 2019 |
Dr Eckstein has more than 20 years of venture capital experience in the biopharmaceutical industry and 10 years of operational experience in drug discovery and development. He is a Kauffman Fellow and a mentor for lifescience entrepreneurs and start-up teams in the area of innovative lifescience and healthcare information technology companies. Before joining Apollo Ventures, Dr Eckstein served as president of SR One for eight years. He is also co-founder and managing director of Action Potential Venture Capital. Previously, he was a general partner at TVM Capital. He is member of Risk Committee.
|
Dr Jakob Dupont | Non-Executive Director | Sep 2022 |
Dr Dupont is an industry and drug development expert with more than 20 years of experience specialising in oncology and other therapeutic areas. Dr Dupont is currently the Executive Venture Partner at Sofinnova Investments. Dr Dupont's experience includes NASDAQ listed Atara Biotherapeutics (NASDAQ: ATRA), where he oversaw all research and development, including three clinical stage programs spanning Phase 1 through to Phase 3, and preclinical programs. Other current directorships include Pyxis Oncology (NASDAQ: PYXS); Avenzo Therapeutics and Flagship Pioneering (Scientific Advisory Board). Former directorships in last three years - Apexigen (NASDAQ: APGN) until August 2023. Dr Dupont is member of the Risk Committee.
|
Ms Kim Drapkin | Non-Executive Director | Jun 2023 |
Ms Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. In addition to Imugene, Ms Drapkin currently serves on the board of directors at Acumen Pharmaceuticals (NASDAQ: ABOS) where she chairs the audit committee and is a member of the compensation committee and LENZ Therapeutics (NASDAQ: LENZ) where she is a member of the compensation and governance committees. Recently, Ms Drapkin was CEO and a board member at Graphite Bio where she led the strategic alternatives process culminating in a reverse merger with LENZ Therapeutics. Prior to that, Ms Drapkin was CFO at Jounce Therapeutics since its inception, playing a role in building Jounce's financial infrastructure. Prior to joining Jounce, Ms Drapkin owned a financial consulting firm where she served as the interim chief financial officer for early stage biotechnology companies. Previously, Ms Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, Ms Drapkin spent ten years in roles of increasing responsibility within the finance organisation at Millennium Pharmaceuticals. Ms Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Other current directorships are held with Acumen Pharmaceuticals (NASDAQ: ABOS); LENZ Therapuetics (NASDAQ: LENZ). Former directorships in last three years - Yumanity Therapeutics (NASDAQ: YMTX); Proteostasis Therapeutics (NASDAQ: PTI). She is chair of risk committee.
|
Mr Michael (Mike) Tonroe | Chief Financial OfficerCompany Secretary | Mar 2023 |
-
|
Monil Shah | Chief Business Officer |
-
|
|
Mike Tonroe | Chief Financial Officer |
-
|
|
Michael (Mike) Tonroe | Chief Financial OfficerCompany Secretary |
-
|
|
Paul Woodard | Chief Medical Officer |
-
|
|
Bradley Glover | Chief Operating Officer |
-
|
|
Nicholas Ede | Chief Technology Officer |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Paul Hopper | 409,071,906 | 5.57% |
JP Morgan | 283,996,697 | 3.86% |
Citicorp Nominees Pty Limited | 266,813,810 | 3.63% |
Mann Family | 265,582,609 | 3.61% |
HSBC Custody Nominees (Australia) Limited i | 213,532,203 | 2.91% |
Dr Nicolas Smith | 118,000,000 | 1.61% |
Netwealth Investments Limited <Wrap Ser Vices A/C> | 85,488,611 | 1.16% |
Mi Ok Chong | 78,416,666 | 1.07% |
BNP Paribas Noms Pty Ltd | 70,407,583 | 0.96% |
National Nominees Pty Ltd | 60,113,645 | 0.82% |
UBS Nominees Pty Ltd | 50,328,041 | 0.68% |
BNP Paribas Noms Pty Ltd <Ib Au Noms Retail Client> | 48,979,324 | 0.67% |
HSBC Custody Nominees (Australia) Limited ii | 29,079,510 | 0.40% |
Mr Phillip Wood | 25,480,000 | 0.35% |
Sve Capital Pty Ltd <Strategic Vision Unit A/C> | 23,000,000 | 0.31% |
Dr Yuman Fong | 22,379,032 | 0.30% |
Dr Jen Eckstein | 20,738,095 | 0.28% |
Dr Lesley Russell | 20,238,095 | 0.28% |
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 20,230,709 | 0.28% |
Mr Scott Spencer Pappin & Mrs Tracey Lee Pappin <Pappin Super Fund A/C> | 20,000,000 | 0.27% |
Jem Investment Fund Holdings Pty Ltd <Jem Invest Fund Family A/C> | 20,000,000 | 0.27% |